Msefsl

CLOSE X

Risk Disclosures on Derivatives

>9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
>On an average, loss makers registered net trading loss close to ₹ 50,000.
>Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
>Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

REMUS PHARMACEUTICALS LTD.

NSE : NABSE : ISIN CODE : INE0O5T01011Industry : TradingHouse : Private

BSE0.000 (0 %)

PREV CLOSE ( ) NA

OPEN PRICE ( ) 0.00

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 0

TODAY'S LOW / HIGH ( )0.00 0.00

52 WK LOW / HIGH ( ) 00

NSE

This Company is not listed in NSE

BSE NSE

1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 21-09 2015

Management Info

Swapnil Jatinbhai Shah - Chairman Arpit Shah - Managing Director

Registered Office

Address 1101 To 1103, South Tower,One 42, B/h Ashok Vatika, Nr. Jayantilal Park,Brts, Ambli Bopal Road,
Ahmedabad,
Gujarat-380054

Phone 079-29999857

Email cs@remuspharma.com

Website www.remuspharma.com

Registrars Details

Link Intime India Pvt Ltd.

5th Floor, 506 to 508,Amarnath Business Centre-1(Abc-1),,Beside Gala Business Center,Nr. St. Xavier’s College, Corner, Off C G Road, Ellis Bridge,Ahmedabad

Listing : NSE

NEWS

21Feb Press Release
Remus Pharmaceuticals Limited has informed the Exchange about Copy of Ne..

20Feb Appointment of Statutory Auditors
Remus Pharmaceuticals Limited has informed the Exchange regarding Notice..

14Feb Outcome of Board Meeting
Remus Pharmaceuticals Limited has informed the Exchange regarding Board..

08Feb Substantial
REMUS PHARMACEUTICALS LIMITED has informed the Exchange regarding Acquis..

08Feb Award of Order/Contract/Project
REMUS PHARMACEUTICALS LIMITED has informed the Exchange regarding Defini..

Financials

Rs. in Millions

	QTR	ANNUAL 24
Net Profit		168.19
Gross Profit		225.24
Operating Profit		237.37
Net Sales		634.96

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

The Yamuna Syndicate (BSE) 30648.35 (5.00%)	M.Cap ( in Cr)942.02
TCI Industries (BSE) 1500.00 (2.95%)	M.Cap ( in Cr)134.52
Brand Concepts (BSE) 753.90 (4.64%)	M.Cap ( in Cr)839.30
Manbro Industries (BSE) 675.45 (5.00%)	M.Cap ( in Cr)33.84
Veritas (India) (BSE) 1400.50 (2.00%)	M.Cap ( in Cr)3754.74

Shareholding Pattern

	PROMOTERS	70.6%
	NON-INSTITUTION	25.49%
	MUTUAL FUNDS/UTI	0%
	FI/BANKS/INSURANCE	0%
	GOVERNMENT	0%
	FII	0%

Mf Holdings

Scheme Name	Hold(%)
No Data Found

Risk Disclosures on Derivatives

Smart Quotes

REMUS PHARMACEUTICALS LTD.